Episode Details
Back to Episodes
Weight Loss Drug Cage Match - Part 2 Study Insights
Published 1 year ago
Description
In Part 1 we looked at the basics of a study that compared the two newest GLP-1 weight loss drugs against each other - Novo Nordisk’s Semaglutide (Wegovy) and Eli Lilly’s Tirzepatide (Zepbound) The trial was funded by Eli Lilly and while many of the authors took money from the makers of both drugs, the only authors (some of whom were statisticians) who were employed by and owned stock in a drug company were from Eli Lilly. While that isn’t proof of bias, it’s certainly a red flag.
Today we’ll look at the study and its findings.
Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe